Cover Image
市場調查報告書 - 217338

RG1678;市場分析及預測

RG1678 - Analysis and Forecasts from 2014 to 2020

出版商 GlobalData
出版日期 內容資訊 英文 30 Pages
價格
RG1678;市場分析及預測 RG1678 - Analysis and Forecasts from 2014 to 2020
出版日期: 2011年07月28日 內容資訊: 英文 30 Pages
簡介

本報告提供精神分裂症治療藥物 RG1678 的平台分析及市場預測,以市場特徵為首,評估分析競爭,開發平台等,未來市場競爭等資訊,為您概述為以下內容。

目錄

1. 目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2. 簡介

  • 2.1 精神分裂症
  • 2.2 症狀
  • 2.3 精神分裂症 市場
  • 2.4 免疫學
  • 2.5 病因論
    • 2.5.1 遺傳的因素
    • 2.5.2 環境的因素
    • 2.5.3 腦結構的異常
  • 2.6 GlobalData 報告指南

3. 精神分裂症: 市場特性

  • 3.1 精神分裂症 市場
  • 3.2 精神分裂症 市場 預測及年複合成長率
  • 3.3 推動力; 精神分裂症 治療藥物市場
    • 3.3.1 專利期間的結束; 主要上市藥
    • 3.3.2 患者群的增加
    • 3.3.3 高處方率
    • 3.3.4 患者的藥物服用遵守率低
    • 3.3.5 高未飽和需求

4. 分類; 精神分裂症

  • 4.1 發病年齡 精神分裂症
    • 4.1.1 兒童 / 青年時期 / 幼年期 精神分裂症
    • 4.1.2 成人的精神分裂症
  • 4.2 相關症狀
    • 4.2.1 妄想型精神分裂症
    • 4.2.2 錯亂型精神分裂症
    • 4.2.3 緊張型精神分裂症
    • 4.2.4 殘餘型精神分裂症
    • 4.2.5 未分化障礙

5. 治療方法; 精神分裂症

  • 5.1 危機解決團隊 (CRT)
  • 5.2 自願及強制性拘留
  • 5.3 抗精神病藥
    • 5.3.1 典型抗精神病藥物
    • 5.3.2 非典型抗精神病藥物
    • 5.3.3 死亡率的增加 - 患有癡呆症相關精神病的老人病患

6. RG1678

  • 6.1 簡介
  • 6.2 作用機制
  • 6.3 臨床研究
  • 6.4 RG1678 開發新藥情形
  • 6.5 銷售額影響因素; RG1678
    • 6.5.1 級一藥
    • 6.5.2 高未飽和需求
    • 6.5.3 安慰劑的安全性簡介
  • 6.6 競爭的激烈程度
  • 6.7 銷售額 預測
    • 6.7.1 目標患者群; RG1678
    • 6.7.2 投藥
    • 6.7.3 市場滲透率
    • 6.7.4 治療的年度成本;
    • 6.7.5 銷售額預測; RG1678

7. 精神分裂症 市場: 附錄

  • 7.1 市場定義
  • 7.2 簡稱
  • 7.3 調查方法
  • 7.4 治療藥物的銷售額預期模式
  • 7.5 諮詢方式
  • 7.6 免責聲明
  • 7.7 資訊來源

表格一覽

  • 表格 1: RG1678, 開發新藥情形
  • 表格 2: RG1678, 安全性簡介比較;安慰劑, 第二階段臨床實驗檢驗
  • 表格 3: RG1678, 年度治療費用預測
  • 表格 4: RG1678, 精神分裂症, 全球市場 銷售額 預測 ($m)
  • 表格 5: RG1678, 精神分裂症, 美國, 銷售額 預測 ($m)
  • 表格 6: RG1678, 精神分裂症, 英國, 銷售額 預測 ($m)
  • 表格 7: RG1678, 精神分裂症, 法國, 銷售額 預測 ($m)
  • 表格 8: RG1678, 精神分裂症, 德國, 銷售額 預測 ($m)
  • 表格 9: RG1678, 精神分裂症, 義大利, 銷售額 預測 ($m)
  • 表格 10: RG1678, 精神分裂症, 西班牙, 銷售額 預測 ($m)
  • 表格 11: RG1678, 精神分裂症, 日本, 銷售額 預測 ($m)

圖表一覽

  • 圖 1: 風險發展; 精神分裂症
  • 圖 2: 發展的環境因素; 精神分裂症
  • 圖 3: 精神分裂症, 全球市場 市場規模預測 ($bn)
  • 圖 4: 分類; 精神分裂症 (以發病年齡為基礎)
  • 圖 5: 藥物模式圖; RG1678
  • 圖 6: RG1678, 精神分裂症, 全球市場 銷售額 預測 ($m)
  • 圖 7: RG1678, 精神分裂症, 美國, 銷售額 預測 ($m)
  • 圖 8: RG1678, 精神分裂症, 英國, 銷售額 預測 ($m)
  • 圖 9: RG1678, 精神分裂症, 法國, 銷售額 預測 ($m)
  • 圖 10: RG1678, 精神分裂症, 德國, 銷售額 預測 ($m)
  • 圖 11: RG1678, 精神分裂症, 義大利, 銷售額 預測 ($m)
  • 圖 12: RG1678, 精神分裂症, 西班牙, 銷售額 預測 ($m)
  • 圖 13: RG1678, 精神分裂症, 日本, 銷售額 預測 ($m)
  • 圖 14: RG1678, 精神分裂症, 全球市場 銷售額分佈預測 - 主要國家 (%)

目錄

Abstract

Summary

GlobalData's pharmaceuticals report, "RG1678 - Analysis and Forecasts from 2014 to 2020" provides RG1678  sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of RG1678
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of RG1678 including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for RG1678 in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Introduction

  • 2.1 Schizophrenia
  • 2.2 Symptoms
  • 2.3 Schizophrenia Market
  • 2.4 Epidemiology
  • 2.5 Etiology
    • 2.5.1 Genetic Factors
    • 2.5.2 Environmental Factors
    • 2.5.3 Abnormal Brain Structure
  • 2.6 GlobalData Report Guidance

3. Schizophrenia: Market Characterization

  • 3.1 Schizophrenia Market
  • 3.2 Schizophrenia Market Forecasts and CAGR
  • 3.3 Drivers of Schizophrenia Therapeutics Market
    • 3.3.1 Patent Expiry of Leading Marketed Drugs
    • 3.3.2 Increasing Patient Pool
    • 3.3.3 High Prescription Rates
    • 3.3.4 Low Patient Compliance Rate
    • 3.3.5 High Unmet Need

4. Classification of Schizophrenia

  • 4.1 Age of Onset of Schizophrenia
    • 4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
    • 4.1.2 Adult Schizophrenia
  • 4.2 Associated Symptoms
    • 4.2.1 Paranoid Schizophrenia
    • 4.2.2 Disorganized Schizophrenia
    • 4.2.3 Catatonic Schizophrenia
    • 4.2.4 Residual Schizophrenia
    • 4.2.5 Undifferentiated Disorder

5. Treatment for Schizophrenia

  • 5.1 Crisis Resolution Teams (CRT)
  • 5.2 Voluntary and Compulsory Detention
  • 5.3 Antipsychotics
    • 5.3.1 Typical Antipsychotics
    • 5.3.2 Atypical Antipsychotics
    • 5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

6. RG1678

  • 6.1 Introduction
  • 6.2 Mechanism of Action
  • 6.3 Clinical Studies
  • 6.4 RG1678 Drug Development Status
  • 6.5 Factors Affecting Sales of RG1678
    • 6.5.1 First in Class Drug
    • 6.5.2 High Unmet Need
    • 6.5.3 Placebo-Like Safety Profile
  • 6.6 Intensity of Competition
  • 6.7 Sales Forecasts
    • 6.7.1 Target Patient Pool of RG1678
    • 6.7.2 Dosing
    • 6.7.3 Market Penetration
    • 6.7.4 Annual Cost of Therapy
    • 6.7.5 Sales Projections of RG1678

7. Schizophrenia Market: Appendix

  • 7.1 Market Definitions
  • 7.2 Abbreviations
  • 7.3 Research Methodology
  • 7.4 Drug Sales Estimates Model
  • 7.5 Contact Us
  • 7.6 Disclaimer
  • 7.7 Sources

List of Tables

  • Table 1: RG1678, Drug Development Status, 2010
  • Table 2: RG1678, Comparison of Safety Profile with Placebo, Phase II Clinical Trials
  • Table 3: RG1678, Annual Treatment Costs, 2014
  • Table 4: RG1678, Schizophrenia, Global, Sales Forecasts ($m), 2014-2020
  • Table 5: RG1678, Schizophrenia, The US, Sales Forecasts ($m), 2014-2020
  • Table 6: RG1678, Schizophrenia, UK, Sales Forecasts ($m), 2014-2020
  • Table 7: RG1678, Schizophrenia, France, Sales Forecasts ($m), 2014-2020
  • Table 8: RG1678, Schizophrenia, Germany, Sales Forecasts ($m), 2014-2020
  • Table 9: RG1678, Schizophrenia, Italy, Sales Forecasts ($m), 2014-2020
  • Table 10: RG1678, Schizophrenia, Spain, Sales Forecasts ($m), 2014-2020
  • Table 11: RG1678, Schizophrenia, Japan, Sales Forecasts ($m), 2015-2020

List of Figures

  • Figure 1: Risk of Developing Schizophrenia
  • Figure 2: Environmental Factors in the Development of Schizophrenia
  • Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 2010-2020
  • Figure 4: Classification of Schizophrenia based on the Age of Disease Onset
  • Figure 5: Drug Model Diagram of RG1678
  • Figure 6: RG1678, Schizophrenia, Global, Sales Forecasts ($m), 2014-2020
  • Figure 7: RG1678, Schizophrenia, The US, Sales Forecasts ($m), 2014-2020
  • Figure 8: RG1678, Schizophrenia, UK, Sales Forecasts ($m), 2014-2020
  • Figure 9: RG1678, Schizophrenia, France, Sales Forecasts ($m), 2014-2020
  • Figure 10: RG1678, Schizophrenia, Germany, Sales Forecasts ($m), 2014-2020
  • Figure 11: RG1678, Schizophrenia, Italy, Sales Forecasts ($m), 2014-2020
  • Figure 12: RG1678, Schizophrenia, Spain, Sales Forecasts ($m), 2014-2020
  • Figure 13: RG1678, Schizophrenia, Japan, Sales Forecasts ($m), 2015-2020
  • Figure 14: RG1678, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2020
Back to Top